Oncoclínicas conclui venda da espanhola Medsir e encerra arbitragem
Oncoclínicas conclui venda da espanhola Medsir e encerra arbitragem
A Oncoclínicas informou nesta terça-feira (22) que sua subsidiária integral Idengene Medicina Diagnóstica concluiu a venda da totalidade de su...
valor.globo.com
September 23, 2026 at 1:07 AM
Oncoclínicas conclui venda da espanhola Medsir e encerra arbitragem
Ciencia cuando ya no queda nada más: "Investigamos un medicamento para personas con metástasis cerebral"
Ciencia cuando ya no queda nada más: "Investigamos un medicamento para personas con metástasis cerebral"
La empresa española MEDSIR estudia los prometedores efectos de un medicamento que se llama HER3-DXd con el que, en las pruebas, 1 de cada 3 pacientes con metástasis cerebral "mantuvieron e incluso mejoraron sus capacidades cognitivas durante el tratamiento"
dozz.es
July 7, 2025 at 1:11 PM
Ciencia cuando ya no queda nada más: "Investigamos un medicamento para personas con metástasis cerebral"
Endividada, Oncoclínicas vende participação na espanhola Medsir por 1 euro: A Oncoclínicas anunciou hoje a venda da participação que possui na empresa espanhola de pesquisa médica Medsir pelo valor simbólico de um euro.O que aconteceuA Oncoclínicas vendeu toda a sua fatia na… #Oncoclínicas #Medsir
Endividada, Oncoclínicas vende participação na espanhola Medsir por 1 euro
A Oncoclínicas anunciou hoje a venda da participação que possui na empresa espanhola de pesquisa médica Medsir pelo valor simbólico de um euro.O que aconteceuA Oncoclínicas vendeu toda a sua fatia na Medsir para a MAJ 3 Capital. O negócio foi fechado p
economia.uol.com.br
September 24, 2026 at 1:37 AM
Endividada, Oncoclínicas vende participação na espanhola Medsir por 1 euro: A Oncoclínicas anunciou hoje a venda da participação que possui na empresa espanhola de pesquisa médica Medsir pelo valor simbólico de um euro.O que aconteceuA Oncoclínicas vendeu toda a sua fatia na… #Oncoclínicas #Medsir
Bring Your Research Ideas to Life — Meet with MEDSIR @wearemedsir at #ASCO25 to Get Started! 👉 buff.ly/BHKdQ7I
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
May 27, 2025 at 11:21 AM
Bring Your Research Ideas to Life — Meet with MEDSIR @wearemedsir at #ASCO25 to Get Started! 👉 buff.ly/BHKdQ7I
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
Oncoclínicas (ONCO3) vende participação na empresa espanhola Medsir
https://www.infomoney.com.br/mercados/oncoclinicas-onco3-vende-participacao-na-empresa-espanhola-medsir/?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios @economia-neg-cios-FlipboardBR
https://www.infomoney.com.br/mercados/oncoclinicas-onco3-vende-participacao-na-empresa-espanhola-medsir/?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios @economia-neg-cios-FlipboardBR
Oncoclínicas (ONCO3) vende participação na empresa espanhola Medsir
A transação foi realizada no contexto da decisão da companhia de desinvestir de ativos non-core
www.infomoney.com.br
September 23, 2026 at 11:56 AM
Oncoclínicas (ONCO3) vende participação na empresa espanhola Medsir
https://www.infomoney.com.br/mercados/oncoclinicas-onco3-vende-participacao-na-empresa-espanhola-medsir/?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios @economia-neg-cios-FlipboardBR
https://www.infomoney.com.br/mercados/oncoclinicas-onco3-vende-participacao-na-empresa-espanhola-medsir/?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios @economia-neg-cios-FlipboardBR
Endividada, Oncoclínicas vende participação na espanhola Medsir por 1 euro
https://economia.uol.com.br/noticias/redacao/2026/09/23/endividada-oncoclinicas-vende-participacao-na-espanhola-medsir-por-1-euro.ghtm?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios […]
https://economia.uol.com.br/noticias/redacao/2026/09/23/endividada-oncoclinicas-vende-participacao-na-espanhola-medsir-por-1-euro.ghtm?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios […]
Original post on flipboard.com
flipboard.com
September 23, 2026 at 1:57 PM
Endividada, Oncoclínicas vende participação na espanhola Medsir por 1 euro
https://economia.uol.com.br/noticias/redacao/2026/09/23/endividada-oncoclinicas-vende-participacao-na-espanhola-medsir-por-1-euro.ghtm?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios […]
https://economia.uol.com.br/noticias/redacao/2026/09/23/endividada-oncoclinicas-vende-participacao-na-espanhola-medsir-por-1-euro.ghtm?utm_source=flipboard&utm_medium=activitypub
Posted into Economia & Negócios […]
Bring Your Research Ideas to Life — Meet with MEDSIR at #ASCO25 to Get Started!
👉 www.medsir.org/events/asco2...
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators & industry
👉 www.medsir.org/events/asco2...
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators & industry
May 15, 2025 at 9:03 AM
Bring Your Research Ideas to Life — Meet with MEDSIR at #ASCO25 to Get Started!
👉 www.medsir.org/events/asco2...
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators & industry
👉 www.medsir.org/events/asco2...
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators & industry
🌀 ALMIA | #ComitéCientífico (II)
👉Dr. JAVIER CORTÉS | IBCC, Medsir, Fundación Contigo, @vhio.bsky.social
👉Dra. DELIA CORTÉS | IVOQA @viamedsalud.bsky.social
#MásTiempoParaVivir #CáncerMetastásico
www.cancermetastasico.es/sobre-nosotr...
👉Dr. JAVIER CORTÉS | IBCC, Medsir, Fundación Contigo, @vhio.bsky.social
👉Dra. DELIA CORTÉS | IVOQA @viamedsalud.bsky.social
#MásTiempoParaVivir #CáncerMetastásico
www.cancermetastasico.es/sobre-nosotr...
September 2, 2025 at 5:49 PM
🌀 ALMIA | #ComitéCientífico (II)
👉Dr. JAVIER CORTÉS | IBCC, Medsir, Fundación Contigo, @vhio.bsky.social
👉Dra. DELIA CORTÉS | IVOQA @viamedsalud.bsky.social
#MásTiempoParaVivir #CáncerMetastásico
www.cancermetastasico.es/sobre-nosotr...
👉Dr. JAVIER CORTÉS | IBCC, Medsir, Fundación Contigo, @vhio.bsky.social
👉Dra. DELIA CORTÉS | IVOQA @viamedsalud.bsky.social
#MásTiempoParaVivir #CáncerMetastásico
www.cancermetastasico.es/sobre-nosotr...
Oncoclínicas vende participação em empresa espanhola por 1 euro
Oncoclínicas vende participação em empresa espanhola por 1 euro
Transação elimina obrigações futuras que poderiam chegar a € 52 milhões e encerra disputa arbitral envolvendo a Medsir
veja.abril.com.br
September 23, 2026 at 2:30 PM
Oncoclínicas vende participação em empresa espanhola por 1 euro
#MEDSIRatASCO
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
#MEDSIRatASCO - #TUXEDO3trial
YouTube video by MEDSIR
www.youtube.com
May 31, 2025 at 3:35 PM
#MEDSIRatASCO
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
Great turnout at the BH-CTI-MEDSIR IIT Think Tank in RCSI today.
@gerryhanna.bsky.social speaking on the growing need for investigator-led trials in Ireland, with a strong room of collaborators focused on what comes next.
Important conversations underway.
#CancerTrials #Oncology
@gerryhanna.bsky.social speaking on the growing need for investigator-led trials in Ireland, with a strong room of collaborators focused on what comes next.
Important conversations underway.
#CancerTrials #Oncology
May 5, 2026 at 1:27 PM
Great turnout at the BH-CTI-MEDSIR IIT Think Tank in RCSI today.
@gerryhanna.bsky.social speaking on the growing need for investigator-led trials in Ireland, with a strong room of collaborators focused on what comes next.
Important conversations underway.
#CancerTrials #Oncology
@gerryhanna.bsky.social speaking on the growing need for investigator-led trials in Ireland, with a strong room of collaborators focused on what comes next.
Important conversations underway.
#CancerTrials #Oncology
Format GoI na dziś 😋
scp-pl.wikidot.com/ambrose-medsir — Ambrose Med'sir
"[...] w przypadku Ambrose Med'sir, wymagałoby to również oceny całkiem zawiłej sytuacji politycznej wokoło miasta i ostatnich wydarzeń na scenie geopolitycznej w które również zamieszana jest Fundacja SCP"
#SCP #SCP-PL #Polska
scp-pl.wikidot.com/ambrose-medsir — Ambrose Med'sir
"[...] w przypadku Ambrose Med'sir, wymagałoby to również oceny całkiem zawiłej sytuacji politycznej wokoło miasta i ostatnich wydarzeń na scenie geopolitycznej w które również zamieszana jest Fundacja SCP"
#SCP #SCP-PL #Polska
January 14, 2025 at 11:09 AM
Format GoI na dziś 😋
scp-pl.wikidot.com/ambrose-medsir — Ambrose Med'sir
"[...] w przypadku Ambrose Med'sir, wymagałoby to również oceny całkiem zawiłej sytuacji politycznej wokoło miasta i ostatnich wydarzeń na scenie geopolitycznej w które również zamieszana jest Fundacja SCP"
#SCP #SCP-PL #Polska
scp-pl.wikidot.com/ambrose-medsir — Ambrose Med'sir
"[...] w przypadku Ambrose Med'sir, wymagałoby to również oceny całkiem zawiłej sytuacji politycznej wokoło miasta i ostatnich wydarzeń na scenie geopolitycznej w które również zamieszana jest Fundacja SCP"
#SCP #SCP-PL #Polska
Novel Combination Therapy Enhances Control of Advanced Prostate Cancer#United_States#Chicago#MEDSIR#Prostate_Cancer#ZZ-FIRST_study
Novel Combination Therapy Enhances Control of Advanced Prostate Cancer
MEDSIR reveals promising results from the ZZ-FIRST study, showing that combined therapy improves disease management in hormone-sensitive prostate cancer.
third-news.com
June 1, 2026 at 10:08 AM
Novel Combination Therapy Enhances Control of Advanced Prostate Cancer#United_States#Chicago#MEDSIR#Prostate_Cancer#ZZ-FIRST_study
Bring Your Research Ideas to Life — Meet with MEDSIR at #ASCO25 to Get Started!
👉 buff.ly/BHKdQ7I
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators and industry partners.
👉 buff.ly/BHKdQ7I
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators and industry partners.
May 23, 2025 at 12:26 PM
Bring Your Research Ideas to Life — Meet with MEDSIR at #ASCO25 to Get Started!
👉 buff.ly/BHKdQ7I
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators and industry partners.
👉 buff.ly/BHKdQ7I
MEDSIR is a global oncology research company that designs and runs innovative, patient-focused clinical trials through agile, independent collaborations with investigators and industry partners.
We're excited to share that the #MEDSIR team will be at the @ascocancer.bsky.social with an oral presentation and two posters. We would like to highlight our studies:
May 22, 2025 at 1:24 PM
We're excited to share that the #MEDSIR team will be at the @ascocancer.bsky.social with an oral presentation and two posters. We would like to highlight our studies:
#GoodMorning MEDSIR
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
June 2, 2025 at 1:59 PM
#GoodMorning MEDSIR
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#GoodMorning MEDSIR!
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
May 31, 2025 at 1:38 PM
#GoodMorning MEDSIR!
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
#MEDSIRatASCO
YouTube video by MEDSIR
www.youtube.com
May 31, 2025 at 9:25 PM
#MEDSIRatASCO
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
MEDSIR invites you to their MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease & ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
November 28, 2025 at 5:45 PM
MEDSIR invites you to their MEDiscussion at #SABCS25 🚨Join top global experts for a high-level exchange on the latest in HER2+, HR+/luminal disease & ctDNA. 👉 buff.ly/qC8Poj0
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
FREE REGISTRATION
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
🗣 Moderator: Dr. Giampaolo Bianchini
#GoodMorning MEDSIR! Big day ahead with the oral presentation of our study #TUXEDO3trial
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
May 30, 2025 at 2:48 PM
#GoodMorning MEDSIR! Big day ahead with the oral presentation of our study #TUXEDO3trial
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
#MEDSIRatASCO
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
10 Years From Now In Oncology
QUICK READ Welcome to '10 Years from Now in Oncology', MEDSIR Linkedin Newsletter TUXEDO-3 Presentation at ASCO 2025 Special Guest: Exclusive Interview with Dr. Matthias Preusser, on TUXEDO-3, an oral...
www.linkedin.com
May 31, 2025 at 9:26 AM
#MEDSIRatASCO
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
🇪🇸 ¿Ya le echaste un vistazo a nuestra newsletter exclusiva desde #ASCO?
👉 Invitado especial: Dr. Matthias Preusser
🗣️ Nos habla sobre #TUXEDO3trial, presentado en ASCO y publicado en Nature Medicine.
👉🏼 Haz clic aquí y no te la pierdas: www.linkedin.com/pulse/10-yea...
👉 Invitado especial: Dr. Matthias Preusser
🗣️ Nos habla sobre #TUXEDO3trial, presentado en ASCO y publicado en Nature Medicine.
👉🏼 Haz clic aquí y no te la pierdas: www.linkedin.com/pulse/10-yea...
10 Years From Now In Oncology
QUICK READ Welcome to '10 Years from Now in Oncology', MEDSIR Linkedin Newsletter TUXEDO-3 Presentation at ASCO 2025 Special Guest: Exclusive Interview with Dr. Matthias Preusser, on TUXEDO-3, an oral...
www.linkedin.com
May 31, 2025 at 9:26 AM
🇪🇸 ¿Ya le echaste un vistazo a nuestra newsletter exclusiva desde #ASCO?
👉 Invitado especial: Dr. Matthias Preusser
🗣️ Nos habla sobre #TUXEDO3trial, presentado en ASCO y publicado en Nature Medicine.
👉🏼 Haz clic aquí y no te la pierdas: www.linkedin.com/pulse/10-yea...
👉 Invitado especial: Dr. Matthias Preusser
🗣️ Nos habla sobre #TUXEDO3trial, presentado en ASCO y publicado en Nature Medicine.
👉🏼 Haz clic aquí y no te la pierdas: www.linkedin.com/pulse/10-yea...
A Great Evening with our friends at MEDSIR here in #SABCS25 for MEDiscussion
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
December 11, 2025 at 7:15 PM
A Great Evening with our friends at MEDSIR here in #SABCS25 for MEDiscussion
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
Amazing Global experts discussing the latest in HER2+, HR+/luminal disease, and ctDNA. 👉 www.medsir.org
Our thanks to:
🎙 Chairs: Dr. Javier Cortés, Dr. Antonio Llombart, Dr. Naoto Ueno
Thank you for joining us!!
A warm invitation to MEDTALK at ESMO 2025, hosted by MEDSIR
Register: www.medsir.org/events/medta...
October 19th, 7:00 PM in Berlin, Germany. Explore how theranostics is revolutionizing oncology by uniting diagnostic imaging and targeted therapy to offer new hope for patients with advanced cancer
Register: www.medsir.org/events/medta...
October 19th, 7:00 PM in Berlin, Germany. Explore how theranostics is revolutionizing oncology by uniting diagnostic imaging and targeted therapy to offer new hope for patients with advanced cancer
June 18, 2025 at 3:56 PM
A warm invitation to MEDTALK at ESMO 2025, hosted by MEDSIR
Register: www.medsir.org/events/medta...
October 19th, 7:00 PM in Berlin, Germany. Explore how theranostics is revolutionizing oncology by uniting diagnostic imaging and targeted therapy to offer new hope for patients with advanced cancer
Register: www.medsir.org/events/medta...
October 19th, 7:00 PM in Berlin, Germany. Explore how theranostics is revolutionizing oncology by uniting diagnostic imaging and targeted therapy to offer new hope for patients with advanced cancer